Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Healio Gastroenterology

September 12, 2022

Obefazimod bests placebo, improves ulcerative colitis in phase 2b induction trial

Les Echos investir

September 7, 2022

Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans la rectocolite hémorragique

La Gazette du Laboratoire

September 7, 2022

Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans la rectocolite hémorragique

MedPage Today

September 7, 2022

First-in-Class Drug Brings Relief in Ulcerative Colitis

La Tribune Bourse

September 6, 2022

Abivax: une publication dans ‘The Lancet’ bien accueillie

  • 1
  • 2
  • 3

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn